Jose Luis Labandeira-Garcia

List of Publications by Year in Descending Order

137 papers	4,922 citations	44 h-index	63 g-index
144 ext. papers	5,702 ext. citations	5.7 avg, IF	5.59 L-index

#	Paper	IF	Citations
137	Olfactomedin 2 deficiency protects against diet-induced obesity.. *Metabolism: Clinical and Experimental*, **2022**, 129, 155122	12.7	1
136	Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.. *Biomedicines*, **2022**, 10,	4.8	2
135	Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity.. *Frontiers in Medicine*, **2022**, 9, 840662	4.9	
134	Dopamine regulates adult neurogenesis in the ventricular-subventricular zone via dopamine D3 angiotensin type 2 receptor interactions. *Stem Cells*, **2021**, 39, 1778-1794	5.8	1
133	Estrogen Deficiency and Colonic Function: Surgical Menopause and Sex Differences in Angiotensin and Dopamine Receptor Interaction. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 1533-1541	6.4	1
132	Interactions between ibuprofen, ACE2, renin-angiotensin system, and spike protein in the lung. Implications for COVID-19. *Clinical and Translational Medicine*, **2021**, 11, e371	5.7	16
131	Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
130	The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons. *Progress in Neurobiology*, **2021**, 199, 101919	10.9	11
129	Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. *Clinical Science*, **2021**, 135, 465-481	6.5	23
128	Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. *Journal of Autoimmunity*, **2021**, 122, 102683	15.5	15
127	Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 9884-9889	5.6	1
126	An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria. *Redox Biology*, **2021**, 46, 102078	11.3	6
125	Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson's disease. *Redox Biology*, **2021**, 46, 102095	11.3	2
124	Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia. *Neurotherapeutics*, **2021**, 18, 998-1016	6.4	3
123	Functional Complexes of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Receptors: Expression in Adult but Not Fetal Lung Tissue. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
122	Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. *Frontiers in Neuroanatomy*, **2020**, 14, 26	3.6	12
121	Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research. *Cytotherapy*, **2020**, 22, 1-5	4.8	1

120	Interaction between brain angiotensin and dopaminergic systems and Parkinson's disease **2020**, 463-477		
119	Is Carotid Body Infection Responsible for Silent Hypoxemia in COVID-19 Patients?. *Function*, **2020**, 2,	6.1	13
118	Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. *Brain, Behavior, and Immunity*, **2020**, 87, 256-271	16.6	30
117	Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. *British Journal of Pharmacology*, **2020**, 177, 5622-5641	8.6	7
116	SARS-CoV-2 as a Factor to Disbalance the Renin-Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production. *Journal of Immunology*, **2020**, 205, 1198-1206	5.3	16
115	Angiotensin AT and AT receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia. *Journal of Neuroinflammation*, **2020**, 17, 243	10.1	7
114	Aging-Related Overactivity of the Angiotensin/AT1 Axis Decreases Sirtuin 3 Levels in the Substantia Nigra, Which Induces Vulnerability to Oxidative Stress and Neurodegeneration. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2020**, 75, 416-424	6.4	10
113	Central nicotine induces browning through hypothalamic □opioid receptor. *Nature Communications* , **2019**, 10, 4037	17.4	17
112	Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson's Disease. *Molecular Neurobiology*, **2019**, 56, 2845-2854	6.2	14
111	Hypothalamic dopamine signaling regulates brown fat thermogenesis. *Nature Metabolism*, **2019**, 1, 811-829	14.6	23
110	Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular-Subventricular Zone. *Cells*, **2019**, 8,	7.9	14
109	Physical Exercise Improves Aging-Related Changes in Angiotensin, IGF-1, SIRT1, SIRT3, and VEGF in the Substantia Nigra. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2018**, 73, 1594-1601	6.4	21
108	Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models. *Molecular Neurobiology*, **2018**, 55, 7297-7316	6.2	56
107	Gene therapy approaches in the non-human primate model of Parkinson's disease. *Journal of Neural Transmission*, **2018**, 125, 575-589	4.3	16
106	Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons. *Molecular Neurobiology*, **2018**, 55, 4763-4776	6.2	13
105	Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans. *Molecular Neurobiology*, **2018**, 55, 5847-5867	6.2	42
104	Glucocerebrosidase expression patterns in the non-human primate brain. *Brain Structure and Function*, **2018**, 223, 343-355	4	5
103	Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB and CB receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia. *Brain, Behavior, and Immunity*, **2018**, 67, 139-151	16.6	65

102	Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death. *Neurotherapeutics*, **2018**, 15, 1063-1081	6.4	35
101	Usefulness of identifying G-protein-coupled receptor dimers for diagnosis and therapy of neurodegenerative diseases and of gliomas. *Histology and Histopathology*, **2018**, 33, 909-917	1.4	1
100	Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly. *Oncotarget*, **2018**, 9, 10834-10846	3.3	7
99	Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines. *Data in Brief*, **2018**, 21, 934-942	1.2	
98	Alzheimer's disease DNA methylome of pyramidal layers in frontal cortex: laser-assisted microdissection study. *Epigenomics*, **2018**, 10, 1365-1382	4.4	13
97	Angiotensin II induces oxidative stress and upregulates neuroprotective signaling from the NRF2 and KLF9 pathway in dopaminergic cells. *Free Radical Biology and Medicine*, **2018**, 129, 394-406	7.8	12
96	Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. *Brain, Behavior, and Immunity*, **2017**, 62, 277-290	16.6	54
95	Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells. *Brain Structure and Function*, **2017**, 222, 2559-2571	4	32
94	Laser capture microdissection protocol for gene expression analysis in the brain. *Histochemistry and Cell Biology*, **2017**, 148, 299-311	2.4	9
93	The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system. *Cell Death and Disease*, **2017**, 8, e3044	9.8	41
92	Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. *Brain Structure and Function*, **2017**, 222, 1767-1784	4	39
91	Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. *Frontiers in Aging Neuroscience*, **2017**, 9, 129	5.3	108
90	Insulin-Like Growth Factor-1 and Neuroinflammation. *Frontiers in Aging Neuroscience*, **2017**, 9, 365	5.3	88
89	Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease. *Stem Cells Translational Medicine*, **2016**, 5, 804-15	6.9	7
88	Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration. *Cell Death and Disease*, **2016**, 7, e2427	9.8	65
87	Aging-related Increase in Rho Kinase Activity in the Nigral Region Is Counteracted by Physical Exercise. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2016**, 71, 1254-7	6.4	9
86	Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum. *Molecular Neurobiology*, **2016**, 53, 5436-45	6.2	5
85	Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging. *Oncotarget*, **2016**, 7, 30049-67	3.3	43

84	Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. *Journal of Neurochemistry*, **2016**, 136, 373-87	6	49
83	Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. *Frontiers in Neuroendocrinology*, **2016**, 43, 44-59	8.9	40
82	Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease. *Neuroscientist*, **2015**, 21, 616-29	7.6	29
81	Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. *Brain Structure and Function*, **2015**, 220, 2721-38	4	70
80	Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. *Molecular Neurobiology*, **2015**, 52, 1408-1420	6.2	36
79	Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum. *Biochemical Pharmacology*, **2015**, 96, 131-42	6	44
78	Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. *Glia*, **2015**, 63, 466-82	9	55
77	Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats. *Neurobiology of Aging*, **2015**, 36, 1194-208	5.6	24
76	Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration. *Oncotarget*, **2015**, 6, 26675-89	3.3	27
75	Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1 *Experimental Neurology*, **2014**, 261, 720-32	5.7	49
74	Aging-related dysregulation of dopamine and angiotensin receptor interaction. *Neurobiology of Aging*, **2014**, 35, 1726-38	5.6	57
73	Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA. *Neuropharmacology*, **2014**, 76 Pt A, 156-68	5.5	33
72	Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. *Neuropharmacology*, **2014**, 85, 1-8	5.5	48
71	Brain renin-angiotensin system and dopaminergic cell vulnerability. *Frontiers in Neuroanatomy*, **2014**, 8, 67	3.6	69
70	Microglial TNF- mediates enhancement of dopaminergic degeneration by brain angiotensin. *Glia*, **2014**, 62, 145-57	9	54
69	Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. *Brain Structure and Function*, **2013**, 218, 373-88	4	72
68	Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. *Age*, **2013**, 35, 1675-90		28
67	Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. *Experimental Neurology*, **2013**, 250, 384-96	5.7	32

66	Neuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson's disease. *Neurobiology of Aging*, **2013**, 34, 902-15	5.6	24
65	Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. *Neurobiology of Disease*, **2013**, 58, 209-19	7.5	58
64	Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. *Movement Disorders*, **2013**, 28, 1337-42	7	61
63	Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. *Neurobiology of Disease*, **2012**, 47, 268-79	7.5	78
62	Unmasking adenosine 2A receptors (A2ARs) in monkey basal ganglia output neurons using cholera toxin subunit B (CTB). *Neurobiology of Disease*, **2012**, 47, 347-57	7.5	3
61	Involvement of PPAR-□n the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. *Journal of Neuroinflammation*, **2012**, 9, 38	10.1	77
60	Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. *Brain*, **2012**, 135, 124-38	11.2	52
59	Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. *Age*, **2012**, 34, 863-80		37
58	Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. *Neurobiology of Aging*, **2012**, 33, 204.e1-11	5.6	64
57	2-Benzazepine nitrones protect dopaminergic neurons against 6-hydroxydopamine-induced oxidative toxicity. *Archiv Der Pharmazie*, **2012**, 345, 598-609	4.3	13
56	Cografting of carotid body cells improves the long-term survival, fiber outgrowth and functional effects of grafted dopaminergic neurons. *Regenerative Medicine*, **2012**, 7, 309-22	2.5	9
55	Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. *American Journal of Neurodegenerative Disease*, **2012**, 1, 226-44	2.5	20
54	Renin angiotensin system and gender differences in dopaminergic degeneration. *Molecular Neurodegeneration*, **2011**, 6, 58	19	27
53	Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. *Journal of Psychopharmacology*, **2011**, 25, 97-104	4.6	107
52	Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra **2011**, 2, 257-74		23
51	Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. *European Journal of Neuroscience*, **2010**, 32, 1695-706	3.5	59
50	Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. *Experimental Neurology*, **2010**, 224, 517-26	5.7	57
49	Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 1130-42	3.1	41

48	The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons. *Neurotoxicity Research*, **2009**, 15, 82-95	4.3	27
47	Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 230-4	7.3	45
46	The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. *Journal of Neurochemistry*, **2009**, 109, 656-69	6	137
45	Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson's disease. *Journal of Neurochemistry*, **2009**, 109, 879-88	6	59
44	Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. *Neurobiology of Disease*, **2008**, 31, 58-73	7.5	151
43	Serotonin decreases generation of dopaminergic neurons from mesencephalic precursors via serotonin type 7 and type 4 receptors. *Developmental Neurobiology*, **2007**, 67, 10-22	3.2	18
42	Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. *Journal of Neurochemistry*, **2007**, 103, 145-56	6	147
41	Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. *Neurobiology of Aging*, **2007**, 28, 555-67	5.6	84
40	Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. *Neurochemical Research*, **2007**, 32, 99-105	4.6	36
39	Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. *Neuropharmacology*, **2006**, 51, 112-20	5.5	68
38	Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage. *Journal of Chemical Neuroanatomy*, **2005**, 29, 113-26	3.2	22
37	Angiotensin II and interleukin-1 interact to increase generation of dopaminergic neurons from neurospheres of mesencephalic precursors. *Developmental Brain Research*, **2005**, 158, 120-2		13
36	Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. *Journal of Neuroscience Research*, **2005**, 81, 865-73	4.4	77
35	Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. *European Journal of Neuroscience*, **2004**, 20, 1489-98	3.5	51
34	Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. *Journal of Neuroscience Research*, **2004**, 76, 551-62	4.4	35
33	Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats. *Experimental Brain Research*, **2003**, 153, 92-9	2.3	19
32	Elimination of serotonergic cells induces a marked increase in generation of dopaminergic neurons from mesencephalic precursors. *European Journal of Neuroscience*, **2003**, 18, 2166-74	3.5	21
31	Host brain regulation of dopaminergic grafts function: role of the serotonergic and noradrenergic systems in amphetamine-induced responses. *Synapse*, **2003**, 47, 66-76	2.4	6

30	Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. *Brain Research*, **2003**, 969, 135-46	3.7	66
29	Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. *Biochemical Pharmacology*, **2002**, 64, 125-35	6	100
28	1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. *Molecular Brain Research*, **2002**, 108, 143-6		47
27	Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2002**, 1586, 155-68	6.9	65
26	Dipyridamole-induced increase in production of rat dopaminergic neurons from mesencephalic precursors. *Neuroscience Letters*, **2002**, 320, 65-8	3.3	9
25	Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants. *Free Radical Biology and Medicine*, **2001**, 31, 986-98	7.8	28
24	Long-term cortical atrophy after excitotoxic striatal lesion: effects of intrastriatal fetal-striatum grafts and implications for Huntington disease. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 786-97	3.1	5
23	N-acetylcysteine enhances production of dopaminergic neurons from mesencephalic-derived precursor cells. *NeuroReport*, **2001**, 12, 3935-8	1.7	18
22	Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. *Journal of Neurochemistry*, **2000**, 74, 1605-12	6	233
21	Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems. *Synapse*, **2000**, 35, 182-91	2.4	10
20	GABAA receptor subunit expression in intrastriatal ventral mesencephalic transplants. *Experimental Brain Research*, **2000**, 135, 331-40	2.3	4
19	Recovery after nigral grafting in 6-hydroxydopamine lesioned rats is due to graft function and not significantly influenced by the remaining ipsilateral or contralateral host dopaminergic system. *Brain Research*, **1999**, 842, 119-31	3.7	4
18	Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. *Journal of Comparative Neurology*, **1999**, 406, 199-206	3.4	34
17	Locomotor-activity-induced changes in striatal levels of preprotachykinin and preproenkephalin mRNA. Regulation by the dopaminergic and glutamatergic systems. *Molecular Brain Research*, **1999**, 70, 74-83		15
16	Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. *Synapse*, **1998**, 28, 71-82	2.4	25
15	Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. *Neuroscience Letters*, **1998**, 245, 151-4	3.3	78
14	Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. *NeuroReport*, **1997**, 8, 3485-8	1.7	41
13	Treadmill running induces striatal Fos expression via NMDA glutamate and dopamine receptors. *Experimental Brain Research*, **1997**, 115, 458-68	2.3	54

12	GABAA receptor alpha 1-subunit-immunopositive neurons in the rat striatum. *Brain Research*, **1996**, 722, 185-9	3.7	16
11	Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression. *Experimental Brain Research*, **1996**, 108, 69-84	2.3	49
10	Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors. *Brain Research*, **1995**, 700, 1-12	3.7	63
9	Comparison between normal developing striatum and developing striatal grafts using drug-induced Fos expression and neuron-specific enolase immunohistochemistry. *Neuroscience*, **1994**, 60, 399-415	3.9	18
8	Cortical stimulation induces fos expression in intrastriatal striatal grafts. *Brain Research*, **1994**, 652, 87-97	3.7	24
7	Development of intrastriatal striatal grafts and their afferent innervation from the host. *Neuroscience*, **1991**, 42, 407-26	3.9	95
6	Distribution of the vestibular neurons projecting to the oculomotor and trochlear nuclei in rabbits. *Brain, Behavior and Evolution*, **1991**, 37, 111-24	1.5	16
5	Location of neurons projecting to the retina in mammals. *Neuroscience Research*, **1990**, 8, 291-302	2.9	34
4	Oculomotor nucleus afferents from the interstitial nucleus of Cajal and the region surrounding the fasciculus retroflexus in the rabbit. *Neuroscience Letters*, **1989**, 101, 11-6	3.3	17
3	The abducens motor and internuclear neurons in the rabbit: retrograde horseradish peroxidase and double fluorescent labeling. *Brain Research*, **1989**, 497, 305-14	3.7	15
2	The retinopetal system in the rat. *Neuroscience Research*, **1988**, 6, 88-95	2.9	21
1	Identification of abducens motoneurons, accessory abducens motoneurons, and abducens internuclear neurons in the chick by retrograde transport of horseradish peroxidase. *Journal of Comparative Neurology*, **1987**, 259, 140-9	3.4	30